{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:11:53Z","timestamp":1776085913677,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Accurate detection and monitoring of monoclonal proteins in multiple myeloma (MM) are critical for diagnosis and treatment guidance. Conventional assays such as serum protein electrophoresis (SPEP), immunofixation electrophoresis (SIFE), and serum-free light chain (SFLC) testing can yield discordant or inconclusive results, particularly in patients with low M-protein levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the concordance and discordance between SIFE and SFLC assays in MM and to assess the clinical utility of the heavy\/light chain (HLC) assay as a complementary quantitative tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 1,310 MM patient samples. The concordance and discordance between SIFE and SFLC were assessed, and the analytical performance of HLC measurements was evaluated relative to conventional assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall discordance rate between SIFE and SFLC was 26.9%, with SIFE\u2013\/SFLC\u2009+\u2009most frequent in light chain MM and SIFE\u2009+\u2009\/SFLC\u2013 observed in patients who achieved a very good partial response (VGPR). HLC strongly correlated with total immunoglobulins (combined immunoglobulin G [IgG]\/immunoglobulin A [IgA],\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u2009=\u20090.99) and SPEP (\n                      <jats:italic>R<\/jats:italic>\n                      <jats:sup>\n                        <jats:italic>2<\/jats:italic>\n                      <\/jats:sup>\n                      \u2009=\u20090.94). HLC ratios demonstrated excellent concordance with SIFE (\n                      <jats:italic>\u03ba<\/jats:italic>\n                      \u2009=\u20090.83, 95% confidence interval [CI] 0.72\u20130.93) but poor agreement with SFLC ratios (\n                      <jats:italic>\u03ba<\/jats:italic>\n                      \u2009=\u20090.01, 95% CI\u2009\u2212\u20090.18\u20130.20). Using the HLC response model, 15 patients classified as having VGPR by the International Myeloma Working Group (IMWG) criteria were reclassified as having a partial response due to a dHLC reduction of\u2009&lt;\u200990%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This large retrospective study provides a comprehensive evaluation of SIFE and SFLC discordance in MM, offering real-world evidence of their complementary diagnostic and monitoring roles. These findings support the integration of HLC testing into existing response assessment strategies to enhance the accuracy of treatment evaluation and the interpretation of discordant results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s44313-026-00130-9","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:43:32Z","timestamp":1772761412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discordance between immunofixation and free light chain assays in multiple myeloma: a retrospective analysis and evaluation of the heavy\/light chain assay for disease monitoring"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2858-3063","authenticated-orcid":false,"given":"Oytip","family":"Nathalang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1102-0766","authenticated-orcid":false,"given":"Yupapin","family":"Onthong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7659-9222","authenticated-orcid":false,"given":"Chonlada","family":"Laoruangroj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6654-6431","authenticated-orcid":false,"given":"Dollapak","family":"Apipongrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"130_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma Nat Rev Dis Primers. 2017;3:17046.","journal-title":"Multiple myeloma Nat Rev Dis Primers"},{"issue":"8","key":"130_CR2","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086\u2013107.","journal-title":"Am J Hematol"},{"issue":"5","key":"130_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: A review. JAMA. 2022;327(5):464\u201377.","journal-title":"JAMA"},{"issue":"suppl_4","key":"130_CR4","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv52\u201361.","journal-title":"Ann Oncol"},{"issue":"6","key":"130_CR5","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1515\/cclm-2015-0580","volume":"54","author":"MA Willrich","year":"2016","unstructured":"Willrich MA, Katzmann JA. Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. Clin Chem Lab Med. 2016;54(6):907\u201319.","journal-title":"Clin Chem Lab Med"},{"issue":"9356","key":"130_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0140-6736(03)12457-9","volume":"361","author":"AR Bradwell","year":"2003","unstructured":"Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet. 2003;361(9356):489\u201391.","journal-title":"Lancet"},{"issue":"10","key":"130_CR7","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.1182\/blood-2008-02-138602","volume":"111","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, Degoey R, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood. 2008;111(10):4908\u201315.","journal-title":"Blood"},{"issue":"6","key":"130_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1309\/LMPHODC7R1L0MEWW","volume":"40","author":"D Siegel","year":"2009","unstructured":"Siegel D, Bilotti E, van Hoeven KH. Serum free light chain analysis for diagnosis, monitoring, and prognosis of monoclonal gammopathies. Lab Med. 2009;40(6):363\u20136.","journal-title":"Lab Med"},{"issue":"3","key":"130_CR9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s12013-015-0655-z","volume":"73","author":"W Li","year":"2015","unstructured":"Li W, Zhou JZ, Chang HR, Dai LJ, Zhu ZL, Feng YF, et al. Comparison of SPE, IFE, and FLC in monitoring patients with multiple myeloma after autologous stem cell transplantation. Cell Biochem Biophys. 2015;73(3):643\u20137.","journal-title":"Cell Biochem Biophys"},{"issue":"3","key":"130_CR10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3324\/haematol.2015.126797","volume":"101","author":"T Dejoie","year":"2016","unstructured":"Dejoie T, Attal M, Moreau P, Harousseau JL, Avet-Loiseau H. Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. Haematologica. 2016;101(3):356\u201362.","journal-title":"Haematologica"},{"issue":"4","key":"130_CR11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1055\/s-0043-1768684","volume":"15","author":"M Shastri","year":"2023","unstructured":"Shastri M, Malhotra P, Kaur H, Aggarwal R. Understanding the constraints and optimization of serum immunofixation electrophoresis and serum free light chains for detecting monoclonal proteins: a single-center experience. J Lab Physicians. 2023;15(4):518\u201323.","journal-title":"J Lab Physicians"},{"issue":"1","key":"130_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1182\/blood-2009-02-205807","volume":"114","author":"S Singhal","year":"2009","unstructured":"Singhal S, Vickrey E, Krishnamurthy J, Singh V, Allen S, Mehta J. The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood. 2009;114(1):38\u20139.","journal-title":"Blood"},{"issue":"1","key":"130_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.14740\/jocmr2802w","volume":"9","author":"G Singh","year":"2017","unstructured":"Singh G. Serum free light chain assay and kappa\/lambda ratio: performance in patients with monoclonal gammopathy-high false negative rate for kappa\/lambda ratio. J Clin Med Res. 2017;9(1):46\u201357.","journal-title":"J Clin Med Res"},{"issue":"4","key":"130_CR14","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3816\/CLML.2010.n.057","volume":"10","author":"PB Wood","year":"2010","unstructured":"Wood PB, McElroy YG, Stone MJ. Comparison of serum immunofixation electrophoresis and free light chain assays in the detection of monoclonal gammopathies. Clin Lymphoma Myeloma Leuk. 2010;10(4):278\u201380.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"130_CR15","first-page":"76","volume":"34","author":"E Kuriakose","year":"2019","unstructured":"Kuriakose E, Narayanan Unni Cheppayil S, Kuzhikandathil Narayanan S, Vasudevan A. A study on free light chain assay and serum immunofixation electrophoresis for the diagnosis of monoclonal gammopathies. Indian J Clin Biochem. 2019;34(1):76\u201381.","journal-title":"Indian J Clin Biochem"},{"issue":"5","key":"130_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13050743","volume":"13","author":"C Napodano","year":"2023","unstructured":"Napodano C, Ioannilli L, Basile V, Gulli F, Carnazzo V, Pignalosa S, et al. Laboratory and clinical settings of Heavy\/Light Chain (HLC) assays in the management of monoclonal gammopathies and multiple myeloma. J Pers Med. 2023;13(5):743.","journal-title":"J Pers Med"},{"issue":"7","key":"130_CR17","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1515\/cclm-2017-0817","volume":"56","author":"JFM Jacobs","year":"2018","unstructured":"Jacobs JFM, Haagen IA, Lodder A, van der Kroft C, de Kat Angelino CM, Croockewit S, et al. Analytical validation of the Hevylite assays for M-protein quantification. Clin Chem Lab Med. 2018;56(7):1169\u201375.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"130_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.17219\/acem\/37036","volume":"23","author":"M Kraj","year":"2014","unstructured":"Kraj M. Immunoglobulin heavy chain\/light chain pairs (HLC, Hevylite\u2122) assays for diagnosing and monitoring monoclonal gammopathies. Adv Clin Exp Med. 2014;23(1):127\u201333.","journal-title":"Adv Clin Exp Med"},{"key":"130_CR19","doi-asserted-by":"crossref","unstructured":"Rios-Tamayo R, Puig N, Algarin M, Garcia de Veas Silva JL, Barbosa N, Encinas C, et al. The current role of the Heavy\/Light Chain assay in the diagnosis, prognosis and monitoring of multiple myeloma: An evidence-based approach. Diagnostics (Basel). 2021;11(11):2020.","DOI":"10.3390\/diagnostics11112020"},{"issue":"2","key":"130_CR20","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/leu.2017.209","volume":"32","author":"M Michallet","year":"2018","unstructured":"Michallet M, Chapuis-Cellier C, Dejoie T, Lombard C, Caillon H, Sobh M, et al. Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients. Leukemia. 2018;32(2):376\u201382.","journal-title":"Leukemia"},{"issue":"1","key":"130_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/leu.2012.159","volume":"27","author":"A Bradwell","year":"2013","unstructured":"Bradwell A, Harding S, Fourrier N, Mathiot C, Attal M, Moreau P, et al. Prognostic utility of intact immunoglobulin Ig\u2019kappa\/Ig\u2019lambda ratios in multiple myeloma patients. Leukemia. 2013;27(1):202\u20137.","journal-title":"Leukemia"},{"issue":"1","key":"130_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/leu.2012.197","volume":"27","author":"H Ludwig","year":"2013","unstructured":"Ludwig H, Milosavljevic D, Zojer N, Faint JM, Bradwell AR, Hubl W, et al. Immunoglobulin heavy\/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia. 2013;27(1):213\u20139.","journal-title":"Leukemia"},{"issue":"5","key":"130_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/ejh.12958","volume":"99","author":"C Greil","year":"2017","unstructured":"Greil C, Ihorst G, Gaiser F, Salzer U, Bisse E, Kastritis E, et al. The serum heavy\/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies. Eur J Haematol. 2017;99(5):449\u201358.","journal-title":"Eur J Haematol"},{"issue":"4","key":"130_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.clml.2018.01.008","volume":"18","author":"K Miyazaki","year":"2018","unstructured":"Miyazaki K, Suzuki K. Abnormal heavy\/light chain ratio and matched pair suppression increase residual disease detection sensitivity in patients with multiple myeloma with deep responses. Clin Lymphoma Myeloma Leuk. 2018;18(4):293\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1-2","key":"130_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.clinbiochem.2012.09.023","volume":"46","author":"F Wolff","year":"2013","unstructured":"Wolff F, Debaugnies F, Rozen L, Willems D, Brohet F, Brauner J, et al. Assessment of the diagnostic performances of IgA heavy and light chain pairs in patients with IgA monoclonal gammopathy. Clin Biochem. 2013;46(1\u20132):79\u201384.","journal-title":"Clin Biochem"},{"issue":"2","key":"130_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/cas.13125","volume":"108","author":"Y Suehara","year":"2017","unstructured":"Suehara Y, Takamatsu H, Fukumoto K, Fujisawa M, Narita K, Usui Y, et al. Abnormal heavy\/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma. Cancer Sci. 2017;108(2):187\u201392.","journal-title":"Cancer Sci"},{"issue":"2","key":"130_CR27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1373\/clinchem.2014.231985","volume":"61","author":"JA Katzmann","year":"2015","unstructured":"Katzmann JA, Willrich MA, Kohlhagen MC, Kyle RA, Murray DL, Snyder MR, et al. Monitoring IgA multiple myeloma: immunoglobulin heavy\/light chain assays. Clin Chem. 2015;61(2):360\u20137.","journal-title":"Clin Chem"},{"issue":"9","key":"130_CR28","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467\u201373.","journal-title":"Leukemia"},{"issue":"1","key":"130_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-1-9","volume":"1","author":"E Koulieris","year":"2012","unstructured":"Koulieris E, Panayiotidis P, Harding SJ, Kafasi N, Maltezas D, Bartzis V, et al. Ratio of involved\/uninvolved immunoglobulin quantification by Hevylite\u2122 assay: clinical and prognostic impact in multiple myeloma. Exp Hematol Oncol. 2012;1(1):9.","journal-title":"Exp Hematol Oncol"},{"issue":"8476","key":"130_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"1","author":"JM Bland","year":"1986","unstructured":"Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307\u201310.","journal-title":"Lancet"},{"issue":"15","key":"130_CR31","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320.","journal-title":"J Clin Oncol"},{"key":"130_CR32","doi-asserted-by":"publisher","first-page":"1056293","DOI":"10.3389\/fonc.2022.1056293","volume":"12","author":"MC Cardenas","year":"2022","unstructured":"Cardenas MC, Inigo B, Ortega I, Palomar MA, Menendez M, Plaza P, et al. Can urine studies be replaced by serum free light chains measurements to assign responses in multiple myeloma patients? Front Oncol. 2022;12:1056293.","journal-title":"Front Oncol"},{"issue":"3","key":"130_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3324\/haematol.2016.154070","volume":"102","author":"P Tacchetti","year":"2017","unstructured":"Tacchetti P, Pezzi A, Zamagni E, Pantani L, Rocchi S, Zannetti BA, et al. Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents. Haematologica. 2017;102(3):104\u20137.","journal-title":"Haematologica"},{"issue":"8","key":"130_CR34","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","volume":"55","author":"JA Katzmann","year":"2009","unstructured":"Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem. 2009;55(8):1517\u201322.","journal-title":"Clin Chem"},{"issue":"5","key":"130_CR35","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.pathol.2019.04.002","volume":"51","author":"HY Ting","year":"2019","unstructured":"Ting HY, Sthaneshwar P, Bee PC, Shanmugam H, Lim M. Heavy\/light chain assay in the monitoring of multiple myeloma. Pathology. 2019;51(5):507\u201311.","journal-title":"Pathology"},{"issue":"Pt 3","key":"130_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/0004563214564225","volume":"52","author":"L Paolini","year":"2015","unstructured":"Paolini L, Di Noto G, Maffina F, Martellosio G, Radeghieri A, Luigi C, et al. Comparison of Hevylite IgA and IgG assay with conventional techniques for the diagnosis and follow-up of plasma cell dyscrasia. Ann Clin Biochem. 2015;52(Pt 3):337\u201345.","journal-title":"Ann Clin Biochem"},{"issue":"2","key":"130_CR37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1128\/CVI.13.2.277-280.2006","volume":"13","author":"TD Jaskowski","year":"2006","unstructured":"Jaskowski TD, Litwin CM, Hill HR. Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis. Clin Vaccine Immunol. 2006;13(2):277\u201380.","journal-title":"Clin Vaccine Immunol"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00130-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00130-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00130-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:37:47Z","timestamp":1776083867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00130-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["130"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00130-9","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved under exempt review by the Institutional Review Board of the Royal Thai Army Medical Department (Project No. S063b\/67_Xmp) and the Human Research Ethics Committee of Thammasat University (Science), HREC-TUSc (COA No. 048\/2568). The study was conducted in accordance with the principles of the Declaration of Helsinki. The requirement for written informed consent was waived by the Institutional Review Board because the study involved the use of leftover clinical specimens and retrospectively collected, de-identified data obtained from medical records.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"16"}}